On Nov 12 , 2009 , all patients assigned to fingolimod 125 mg were switched to the 05 mg dose in a blinded manner after a review of data from other phase 3 trials and recommendation from the data and safety monitoring board , but were analysed as being in the 125 mg group in the primary outcome analysis .